Precision BioSciences Inc (OQ:DTIL)
Business Focus: Biotechnology & Medical Research
Apr 16, 2024 04:15 pm ET
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain rights for the programs following Prevail Therapeutics’ decision to conclude the collaboration. Precision uses its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision. The collaboration began in January 2021 and was amended in
Mar 27, 2024 06:45 am ET
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.
Mar 20, 2024 04:30 pm ET
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on March 27, 2024.
Mar 19, 2024 07:00 am ET
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced a poster presentation highlighting new data for the Company’s PBGENE-PMM program, evaluating an ARCUS nuclease as a potential treatment for m.3243-associated primary mitochondrial myopathy (PMM). These data are being presented at the Mitochondrial Medicine – Therapeutic Development Annual Conference, being held from March
Mar 06, 2024 08:45 am ET
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that its partner iECURE has received approval from the U.K. Medicines & Healthcare products Regulatory Agency (MHRA) for the company’s Clinical Trial Authorization (CTA) application to expand the Phase 1/2 OTC-HOPE study evaluating ECUR-506 into the U.K. The OTC-HOPE study is investigating ECUR-506, incorporating an ARCUS nuc
Mar 01, 2024 06:30 am ET
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it has agreed to sell to the public by way of an underwritten offering 2,500,000 shares of its common stock and accompanying warrants to purchase up to 2,500,000 shares of common stock at a combined offering price of $16.00 price per share, for total gross proceeds of $40.0 million, before deducting underwriting d
Feb 29, 2024 04:01 pm ET
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced the commencement of a proposed underwritten public offering of its common stock and accompanying warrants to purchase shares of common stock, including pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers. All shares of common stock, pre-funded warrants and accompanying war
Feb 20, 2024 07:00 am ET
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it had granted Caribou Biosciences, Inc., a leading CRISPR genome-editing cell therapy company, a non-exclusive, worldwide license, with the right to sublicense, to one of Precision’s foundational cell therapy patent families for use with CRISPR in the field of human therapeutics.
Feb 14, 2024 07:00 am ET
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
“We believe the regulatory feedback we have received to date informs and strengthens our clinical strategy and provides a clear pathway towards an IND and/or CTA filing for our lead gene editing program PBGENE-HBV,” said Michael Amoroso, President and Chief Executive Officer at Precision BioSciences. “Based on this feedback, we have initiated the final preclinical studies as well as site selection efforts as we move towards clinical readiness. We look forward to filing regulatory applications in 2024 and continue to believe that PBGENE-HBV has the potential to achieve a functional cure for pat
Feb 13, 2024 07:00 am ET
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that Naresh Tanna, Chief of Staff to the CEO, has been promoted to Vice President of Investor Relations to enhance and expand its IR program and communications with shareholders.
Feb 12, 2024 07:00 am ET
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today received an upfront cash payment and equity investment from TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer. This is the first in a series of payments, with Precision to receive a total of $17.5 million in upfront and
Feb 09, 2024 07:00 am ET
Precision BioSciences to Effect a Reverse Stock Split
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on February 13, 2024, after close of trading on The Nasdaq Capital Market. The Company’s common stock is expected to commence trading on a split-adjuste
Jan 09, 2024 07:00 am ET
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced completion of a strategic transaction with TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer.
Jan 09, 2024 07:00 am ET
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of A
TG Therapeutics, Inc. (NASDAQ: TGTX), “the Company,” today announced that it has entered into an agreement with Precision BioSciences, Inc. (NASDAQ GS: DTIL) to acquire a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel), an...
Dec 13, 2023 08:20 am ET
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that its partner iECURE has received approval from the Australian Therapeutic Goods Administration for the initiation of a first-in-human Phase 1/2 trial evaluating ECUR-506, incorporating an ARCUS nuclease for the treatment of Ornithine Transcarbamylase (OTC) deficiency in pediatric (or neonatal) patients.
Dec 04, 2023 07:00 am ET
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “
Nov 30, 2023 07:00 am ET
Precision BioSciences to Present at Hep-DART 2023
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.
Nov 28, 2023 07:00 am ET
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”). The inducement award consists of an option to purchase (“stock op
Nov 21, 2023 08:31 am ET
Thinking about buying stock in Precision BioSciences, Cadence Design Systems, Costco Wholesale, Can Fite Biopharma, or Marpai?
NEW YORK, Nov. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DTIL, CDNS, COST, CANF, and MRAI.
Nov 14, 2023 08:55 am ET
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 15-16, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Nov 13, 2023 07:05 am ET
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, announced that the company will present late-breaking data today at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting being held in Boston, MA. The poster highlights preclinical data demonstrating PBGENE-HBV’s ability to eliminate cccDNA and inactivate hepatitis B virus (HBV) DNA, meriting further
Nov 11, 2023 08:22 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Precision BioSciences, Inc. (NASDAQ: DTIL) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Precision BioSciences, Inc. (NASDAQ: DTIL) (“Precision”) on behalf of the company’s investors. Since November 2022, shares of Precision’s common stock have declined in value from a trading price...
Nov 10, 2023 07:00 am ET
Precision BioSciences to Present at Upcoming Sidoti Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the Sidoti November Micro Cap Conference taking place November 15-16, 2023.
Nov 09, 2023 07:00 am ET
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that an abstract featuring preclinical data for its wholly owned PBGENE-HBV program has been accepted for late-breaker presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Boston, MA on November 10-14, 2023.
Nov 07, 2023 07:00 am ET
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.
Nov 01, 2023 07:00 am ET
Precision BioSciences to Report Third Quarter Results on November 7, 2023
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that it will publish financial results for the third quarter 2023 and provide a business update on November 7, 2023.
Oct 26, 2023 07:30 am ET
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present two posters at the ESGCT 30th Annual Congress that highlight ARCUS’ differentiated ability to make efficient, durable, and targeted insertion edits in non-human primates (NHPs), as well as preclinical data demonstrating the potential of ARCUS to achieve large excision of
Oct 23, 2023 07:00 am ET
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference taking place October 25, 2023.
Oct 12, 2023 08:00 am ET
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that two abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for poster presentations at the upcoming Congress on October 24-27, 2023, in Brussels, Belgium.
Sep 27, 2023 07:00 am ET
Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genomes.” Once issued, the patent arising from this application will have a standard expiration date in April 2042.
Sep 12, 2023 07:00 am ET
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that the Company plans to highlight its current development programs, pipeline updates, and underlying ARCUS platform technology during a virtual R&D Day to be held today at 9:00 AM ET.
Sep 06, 2023 07:00 am ET
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that members of management will participate in the following investor conferences in the month of September:
Aug 31, 2023 07:00 am ET
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced that it will host its in vivo gene editing R&D Day on Tuesday, September 12, 2023 from 9:00-11:30 AM ET.
Aug 15, 2023 07:04 pm ET
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion of a strategic transaction with Imugene Limited (ASX: IMU) for global rights to Azercabtagene Zapreleucel (azer-cel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs
Aug 04, 2023 07:15 am ET
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.
Aug 01, 2023 05:00 pm ET
Precision BioSciences to Report Second Quarter Results on August 4, 2023
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it will publish financial results for the second quarter 2023 and provide a business update on August 4, 2023.
Jul 27, 2023 07:30 am ET
Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration (FDA) for its lead investigational allogeneic CAR T therapy azercabtagene zapreleucel (azer-cel).
Jun 22, 2023 07:00 am ET
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the company will present positive preclinical data from its PBGENE-HBV development program for the treatment of patients with chronic hepatitis B during an oral presentation (Abstract #OS-034) Thursday, June 22, 2023 at the European Association for Study of the Liver (EASL) Congress 2023 in Vienna, Austria.
Jun 05, 2023 07:00 am ET
Precision BioSciences to Present at Upcoming June Investor Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that members of management will participate in the following investor conferences in June 2023:
May 31, 2023 07:15 am ET
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced program updates across its allogeneic CAR T pipeline. The Company highlighted new interim clinical data for its lead candidate, azercabtagene zapreleucel (azer-cel), as a potential first-in-class allogeneic CD19 CAR T for the growing CAR T relapsed patient population with DLBCL. The Company also provided the first clinical update on PBCAR19B stealth cell, which is in development as a potential best-in
May 25, 2023 07:00 am ET
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will share an update on its allogeneic CAR T programs during a company-hosted webcast and conference call on May 31, 2023 at 8:30 AM ET.
May 24, 2023 08:00 am ET
Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will participate in the Stifel Genetic Medicines Day taking place May 30, 2023.
May 19, 2023 07:00 am ET
Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the company will present preclinical data demonstrating the potential of ARCUS in vivo gene editing for large gene excisions toward the goal of treating Duchenne muscular dystrophy (DMD) at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting. The oral presentation, titled “ARCUS-Mediated Excision of the “Hot Spot” Region of the Human Dystrophin Gene for t
May 12, 2023 05:06 pm ET
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that its late-breaking abstract presenting preclinical in vivo gene editing data for its PBGENE-DMD program, being developed for the potential treatment of Duchenne muscular dystrophy (DMD), is available through the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting website at
May 09, 2023 07:00 am ET
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.
May 08, 2023 04:30 pm ET
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on April 27, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”). The inducement awards consist of options to purchase (“stock options”) an aggregate of 259,641 shares of Precision’s common stock, par value $0.000
May 02, 2023 07:00 am ET
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.
Apr 20, 2023 08:00 am ET
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an upcoming scientific presentation of preclinical data from its PBGENE-HBV program. PBGENE-HBV is designed to potentially eliminate hepatitis B virus (HBV) by targeting viral covalently closed circular DNA (cccDNA) in vivo. An abstract relating to the PBGENE-HBV program was selected for an oral presentation at the Global Hepatitis Summit 2023, being held April 25-28, 2023 in Paris, France.
Apr 19, 2023 04:22 pm ET
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that a late-breaking abstract featuring preclinical data from its PBGENE-DMD program for the potential treatment of Duchenne muscular dystrophy (DMD), was selected for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting being held May 16-20, 2023 in Los Angeles, CA.
Apr 18, 2023 08:00 am ET
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that a late-breaking abstract featuring preclinical data from its PBGENE-DMD program for the potential treatment of Duchenne muscular dystrophy (DMD), was selected for an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting being held May 16-20, 2023 in Los Angeles, CA.
Apr 13, 2023 07:00 am ET
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/606,856, titled “Engineered meganucleases specific for recognition sequences in the PCSK9 gene.” Corresponding international applications in this family have also been allowed in Europe, Australia, Mexico, Japan, and Israel since October 2022. Once issued, patents arising from th
Mar 27, 2023 07:00 am ET
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days taking place April 3-4, 2023.
Mar 09, 2023 07:00 am ET
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.
Mar 02, 2023 07:00 am ET
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2022 and provide a business update on March 9, 2023.
Feb 24, 2023 07:00 am ET
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT).
Feb 22, 2023 07:00 am ET
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.
Feb 14, 2023 07:00 am ET
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on February 9, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”). The inducement awards consist of options to purchase (“stock options”) an aggregate of 159,097 shares of Precision’s common stock, par value $0.0
Jan 09, 2023 07:30 am ET
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.
Jan 06, 2023 07:00 am ET
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel,
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) provided supportive Type C feedback on the Company’s CMC processes and analytical methods for azercabtagene zapreleucel (azer-cel; PBCAR0191). Azer-cel is Precision BioSciences lead allogeneic CAR T candidate being evaluated for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) in subjects who have relapsed following autologous CAR T treatment.
Dec 10, 2022 10:00 am ET
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hemato
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today presented a novel, product-attributes analysis of its lead CD19 allogeneic CAR T candidate, Azercabtagene Zapreleucel (azer-cel; PBCAR0191) that shows a relationship between CAR T cell composition and effective cell dose with pharmacokinetics, pharmacodynamics, and clinical outcomes. Data from this analysis, Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate
Nov 10, 2022 05:00 pm ET
Precision BioSciences Announces Change to its Board of Directors
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. Raymond Schinazi is stepping down from the company’s Board of Directors and will continue as a member of the company’s SAB, lending his deep expertise in antiviral drug discovery and development.
Nov 08, 2022 07:00 am ET
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
Nov 04, 2022 07:19 pm ET
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on November 2, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”). The inducement awards consist of options to purchase (“stock options”) an aggregate of 272,352 shares of Precision’s common stock, par value $0.0
Nov 03, 2022 09:40 am ET
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes of the company’s lead CD19 candidate, Azercabtagene Zapreleucel (azer-cel) was accepted for poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 10-13, 2022 in New Orleans, Louisiana. Precision is currently evaluating azer-cel in a Phase 1/2a clinical tri
Nov 02, 2022 07:00 am ET
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the third quarter 2022 and provide a business update on November 8, 2022.
Oct 26, 2022 07:00 am ET
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso, President and Chief Executive Officer of Precision BioSciences (the “Company”) under the Company’s 2021 Employment Inducement Incentive Award Plan. The inducement grant was approved by the Company’s Compensation Committee.
Oct 11, 2022 03:00 am ET
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre.
Sep 22, 2022 07:00 am ET
Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.
Sep 07, 2022 07:00 am ET
Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
Sep 02, 2022 07:00 am ET
Precision BioSciences Announces Senior Leadership Organizational Changes
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team reporting to Michael Amoroso, Chief Executive Officer (CEO).
Aug 08, 2022 07:00 am ET
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.
Aug 01, 2022 07:00 am ET
Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022.
Jul 25, 2022 07:00 am ET
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on July 19, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”). The inducement awards consist of options to purchase (“stock options”) an aggregate of 583,302 shares of Precision’s common stock, par va
Jun 27, 2022 07:00 am ET
Precision BioSciences Announces Closing of Underwritten Offering of Common Stock
Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. All of the shares of common stock were offered by the Company. The Company intends to use the net proceeds of
Jun 22, 2022 08:30 am ET
Thinking about buying stock in Revlon, Mereo BioPharma, Precision BioSciences, Catalyst Biosciences, or La-Z-Boy?
NEW YORK, June 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for REV, MREO, DTIL, CBIO, and LZB.
Jun 21, 2022 05:25 pm ET
Precision BioSciences Announces $50 Million Offering of Common Stock
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately $50.0 million. The offering is expected to close on or about June 24, 2022, subject to customary closing conditions. All shares of common stock to be sold in the offering will be sold by Precision BioSciences. Precision BioSciences intends to use the
Jun 21, 2022 05:00 pm ET
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the “Agreement”). As part of the Agreement, Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a “safe harbor” location in the genome as a potential one-time transformative tr
Jun 08, 2022 09:31 am ET
Thinking about buying stock in Energy Focus, Precision BioSciences, Full Truck Alliance, Invacare Corp, or Bilibili?
NEW YORK, June 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EFOI, DTIL, YMM, IVC, and BILI.
Jun 08, 2022 07:00 am ET
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced its latest program updates across its allogeneic CAR T pipeline. The Company provided new clinical data and outlined the opportunity for its lead candidate, PBCAR0191, as a potential first-in-class allogeneic CD19 CAR T for the growing autologous CAR T relapsed patient population with aggressive lymphomas. Precision also shared updates on its PBCAR19B and PBCAR269A candidates in development as potenti
Jun 03, 2022 07:30 am ET
Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will share an update on its allogeneic CAR T programs during a company-hosted webcast and conference call on June 8, 2022 at 8:00 AM ET.
Jun 03, 2022 07:00 am ET
Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Healthcare Conference taking place June 8-10, 2022.
Jun 02, 2022 04:35 pm ET
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, effective on May 23, 2022 and May 31, 2022, respectively (the “Grant Dates”), the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”). The inducement awards consist of options to purchase (“stock options”) an agg
May 31, 2022 08:00 am ET
Precision BioSciences Appoints Melinda Brown to Board of Directors
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company’s Board of Directors and Chair of the Board’s Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies.
May 23, 2022 08:00 am ET
Precision BioSciences Appoints Juli Blanche as Chief People Officer
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Juli Blanche has been appointed Chief People Officer and a member of the senior leadership team at Precision BioSciences. Ms. Blanche is a human resources (HR) executive with over 25 years of strategic business partnership and enterprise leadership experience in the pharmaceutical and financial services industries. She most recently joins Precision BioSciences from Bristol-Myers Squibb (BMS) whe
May 18, 2022 07:00 am ET
Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced preclinical research from its ongoing in vivo gene editing program targeting hepatitis B virus (HBV) has been published online in Molecular Therapy. Data from this study, “
May 16, 2022 07:00 am ET
Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced preclinical data will be presented this week on ARCUS genome editing including two oral presentations and two posters at the American Society of Gene & Cell Therapy (ASGCT), May 16-19, 2022 at the Walter E. Washington Convention Center in Washington, D.C.
May 12, 2022 07:00 am ET
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on May 6, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”). The inducement awards consist of options to purchase (“stock option”) an aggregate of 401,905 shares of Precision’s common stock, par value
May 09, 2022 07:00 am ET
Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.
May 02, 2022 04:35 pm ET
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that four abstracts, including one from a research and license collaboration, were accepted by the American Society of Gene & Cell Therapy (ASGCT) and will be presented as posters and oral presentations at the upcoming annual meeting on May 16-19, 2022 at the Walter E. Washington Convention Center in Washington, D.C.
May 02, 2022 07:00 am ET
Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2022 and provide a business update on May 9, 2022. Precision BioSciences also announced that Michael Amoroso, Chief Executive Officer will participate in the H.C. Wainwright Global Investment Conference on May 24, 2022.
Mar 15, 2022 07:00 am ET
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021.
Mar 08, 2022 07:30 am ET
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2021 and provide a business update on March 15, 2022.
Jan 04, 2022 07:00 am ET
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that Michael Amoroso, Chief Executive Officer will present a corporate update at the Annual J.P. Morgan Health Care Conference taking place virtually January 10-13, 2022. Precision Co-Founder and Chief Scientific Officer, Derek Jantz, Ph.D., Chief Financial Officer, Alex Kelly and Chief Medical Officer, Alan List, M.D., will join Michael for Q&A.
Dec 21, 2021 07:00 am ET
Precision BioSciences Completes Spin-Out of Elo Life Systems
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary and creat
Dec 11, 2021 04:30 pm ET
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD)1 presented at the 63rd American Society of Hematology (ASH) Annual Meeting.
Dec 06, 2021 04:49 pm ET
Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will review interim data results presented at the 63rd American Society of Hematology Annual Meeting from the PBCAR0191 CD19 allogeneic CAR T program and provide other CAR T program updates during a company-hosted webcast and conference call on Saturday, December 11, 2021 at 7:30 PM ET.
Dec 03, 2021 04:03 pm ET
Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will present preclinical data for its chronic hepatitis B virus (HBV) program at the HEP DART 2021 conference taking place in Cabo San Lucas, Mexico, December 5 – 9, 2021.
Nov 10, 2021 07:00 am ET
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2021 and provided a business update.
Nov 09, 2021 08:15 am ET
Nov 08, 2021 07:30 am ET
Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Sam Wadsworth, Ph.D., Chief Scientific Officer of Ultragenyx Gene Therapy, an operating unit of Ultragenyx Pharmaceutical Inc., and Shari Lisa Piré, J.D., Chief Legal & Sustainability Officer at Plume Design, have been appointed to the Company’s Board of Directors.
Nov 04, 2021 09:01 am ET
Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meet
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that investigators involved with the Phase 1/2a study of PBCAR0191 in Relapsed/Refractory (R/R) non-Hodgkin’s lymphoma (NHL) and B-cell acute lymphoblastic leukemia (B-ALL), will present new data during two oral presentations at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place December 11-14, 2021.
Nov 03, 2021 07:00 am ET
Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the third quarter 2021 and provide a business update on November 10, 2021.
Oct 21, 2021 07:00 am ET
Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder, will present at the Jefferies Virtual Gene Therapy/Gene Editing Summit, being held October 27-28, 2021.
Sep 27, 2021 08:30 am ET
Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso, newly appointed President and Chief Executive Officer of Precision BioSciences.
Sep 27, 2021 07:00 am ET
Precision BioSciences Appoints Michael Amoroso Chief Executive Officer
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the Company’s President and Chief Executive Officer and a member of the Precision BioSciences Board of Directors, in each case effective October 15, 2021. Mr. Amoroso will succeed Matt Kane, Co-Founder, President and Chief Executive Officer, who is expected to serve as an advisor to the Company to help ensure a smooth transition.
Sep 10, 2021 07:00 am ET
Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021.
Sep 09, 2021 07:01 am ET
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced a license and collaboration agreement under which iECURE plans to advance Precision’s PBGENE-PCSK9 candidate into Phase 1 studies and gain access to Precision’s PCSK9-directed ARCUS nuclease to develop additional gene editing therapies for genetic
Sep 09, 2021 07:01 am ET
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today provided strategic business updates on its in vivo gene editing pipeline during the Company’s first gene editing R&D event.
Sep 02, 2021 02:00 am ET
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Cand
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS), a clinical stage biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announced an exclusive license agreement to explore Tiziana’s foralumab, a fully human anti-CD3 monoclonal antibody (mAb), as an agent to induce tolerance of allogeneic CAR T cells to potentially improve the clin
Sep 02, 2021 02:00 am ET
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Cand
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS),...
Aug 25, 2021 07:00 am ET
Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will host its first R&D event focused on in vivo gene editing at 8:00 am ET on Thursday, September 9, 2021.
Aug 12, 2021 07:00 am ET
Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
Aug 05, 2021 07:00 am ET
Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will publish financial results for the second quarter 2021 and provide a business update on August 12, 2021.
Jul 01, 2021 07:00 am ET
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that the first patient has been dosed in its Phase 1 clinical trial with PBCAR19B, an immune evading allogeneic CAR T stealth cell candidate for patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
Jun 28, 2021 08:30 am ET
Thinking about buying stock in Anavex Life Sciences, Arbutus Biopharma, MannKind, Perion Network, or Precision BioSciences?
NEW YORK, June 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, ABUS, MNKD, PERI, and DTIL.
Jun 28, 2021 07:00 am ET
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the combination arm of Precision’s Phase 1/2a trial evaluating PBCAR269A. In the study, Precision’s investigational allogeneic BCMA-targeted CAR T cell the
Jun 04, 2021 07:00 am ET
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma
Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced encouraging progress on two strategies designed to optimize the durability of allogeneic CAR T therapy in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). The Company reported updated interim results from its Phase 1/2a study of PBCAR0191, the Company’s investigational, off-the-shelf, allogeneic CAR T cell therapy targeting CD19. As of May 21, 2021, 12 patients with
Jun 01, 2021 07:00 am ET
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in Nature Communications that reports preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo.
May 27, 2021 07:00 am ET
Precision BioSciences Appoints Alex Kelly as Chief Financial Officer
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced the appointment of Alex Kelly as Chief Financial Officer. Alex joined Precision BioSciences in October 2020 as Chief Corporate Affairs Officer and has served as the company’s Interim Chief Financial Officer since December 2020. He will continue to serve as the company’s principal financial officer, reporting directly to Matt Kane, Chief Executive Officer and oversee the company’s fina
May 26, 2021 07:00 am ET
Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference
Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and co-founder, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference being held from June 1-4, 2021.
May 19, 2021 05:00 pm ET
Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that additional data from its Phase 1/2a study of PBCAR0191, the Company’s first generation, off-the-shelf allogeneic CAR T candidate targeting CD19 will be presented at the 2021 American Society of Clinical Oncology (ASCO) Meeting being held virtually June 4-8, 2021.
May 13, 2021 07:00 am ET
Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.
May 11, 2021 07:00 am ET
New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced new in vivo data resulting from a preclinical research collaboration with investigators at the University of Pennsylvania presented today at the 2021 American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting.
May 06, 2021 07:00 am ET
Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will publish first quarter 2021 financial results and provide a business update on Thursday, May 13, 2021.
May 03, 2021 07:00 am ET
Precision BioSciences Announces Paper Presentation at the Association for Research in Vision and Ophthalmology 2021 Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, announced today that the following paper presentation, highlighting preclinical research using its ARCUS® genome editing platform for autosomal dominant Retinitis Pigmentosa (adRP), will be presented today at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
Apr 27, 2021 04:35 pm ET
Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that the following poster, highlighting a preclinical research collaboration using its ARCUS® genome editing platform for treatment of transthyretin amyloidosis (ATTR), will be presented at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, scheduled for May 11-14, 2021.
Apr 15, 2021 04:36 pm ET
Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alan List, M.D. has been appointed as the Company’s Chief Medical Officer and a member of the senior leadership team at Precision BioSciences. Dr. List is a world-renowned hematologist with extensive academic and clinical experience in the research and development of hematology and oncology products. He has led clinical development programs for multiple FDA-approved drugs to trea
Apr 15, 2021 04:10 pm ET
Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs
Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it has entered into a Program Purchase Agreement to reacquire all global development and commercialization rights for all CAR T partnered programs covered under its Development and Commercial License Agreement with Servier. This includes its two clinical stage CD19-targeting allogeneic CAR T candidates, PBCAR0191 and PBCAR19B stealth cell, as well as four additional product targets.
Apr 12, 2021 07:06 am ET
Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Stanley R. Frankel, M.D. has been appointed as a Director on the Company’s Board of Directors and a member of the Board’s Science and Technology (S&T) Committee. Dr. Frankel is a hematologist-oncologist with extensive academic and industry experience in the research, clinical development, and commercialization of immuno-oncology and cellular therapies. He has led clini
Apr 09, 2021 04:05 pm ET
Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series
Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder will participate in a fireside chat at the Truist Securities 2021 Life Sciences Virtual Series.
Apr 06, 2021 08:35 am ET
Precision BioSciences Announces CEO Transition Plan
Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a Chief Executive Officer transition plan...
Mar 29, 2021 07:00 am ET
Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will participate in the Guggenheim...
Mar 18, 2021 07:00 am ET
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome editing platform, today announced financial results for the fourth quarter and fiscal year ended...
Mar 12, 2021 07:00 am ET
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year 2020 financial results and provide a business update on Thursday, March 18, 2021. About Precision...
Mar 02, 2021 07:00 am ET
Precision BioSciences to Present at Upcoming Virtual Investor Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced management will participate in the...
Feb 19, 2021 07:30 am ET
Thinking about buying stock in Energous Corp, Casa Systems, Citius Pharmaceuticals, Creative Realities, or Precision BioSciences?
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, CASA, CTXR, CREX, and DTIL.
Feb 19, 2021 07:00 am ET
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company, today announced the publication of a paper in Molecular Therapy describing three-year follow-up data showing long-term stable reduction of low-density lipoprotein...
Feb 04, 2021 07:00 am ET
Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Oncology...
Jan 25, 2021 07:00 am ET
Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS® genome editing platform, today announced it has received a Notice of Allowance from the U.S. Patent and...
Jan 21, 2021 07:30 am ET
Thinking about buying stock in Celsion Corp, Jaguar Health, Precision BioSciences, electroCore, or Lipocine?
NEW YORK, Jan. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, JAGX, DTIL, ECOR, and LPCN.
Jan 19, 2021 07:30 am ET
Thinking about buying stock in DBV Technologies, Endra Life Sciences, Precision BioSciences, Sorrento Therapeutics, or Aldeyra Therapeutics?
NEW YORK, Jan. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DBVT, NDRA, DTIL, SRNE, and ALDX.
Jan 19, 2021 07:00 am ET
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS® genome editing platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted...
Jan 07, 2021 07:00 am ET
Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the closing of its in vivo gene editing research...
Jan 04, 2021 07:00 am ET
Precision BioSciences to Present at the Annual J.P. Morgan Healthcare Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that Matt Kane, Co-founder and Chief Executive Officer and...
Dec 14, 2020 12:00 am ET
Precision BioSciences Announces Executive Leadership Change
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that Abid Ansari, Chief Financial Officer, notified the...
Dec 11, 2020 11:00 am ET
Elo Life Systems Publishes the Most Detailed Genome Map in the Industry to Improve Quality and Supply Chain Stability of Vanilla
Elo Life Systems, a technology driven food and agriculture company headquartered in Durham, N.C., today announced publication of the most comprehensive genome sequence of commercial vanilla species to date. The data, which Elo developed with...
Dec 04, 2020 06:30 am ET
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced positive interim clinical results from its Phase 1/2a study...
Nov 24, 2020 04:05 pm ET
Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that its Chief Scientific Officer, Derek Jantz, Ph.D.,...
Nov 20, 2020 07:30 am ET
Thinking about buying stock in Precision BioSciences, Waitr Holdings, Transocean, FireEye, or Gevo?
NEW YORK, Nov. 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DTIL, WTRH, RIG, FEYE, and GEVO.
Nov 20, 2020 06:00 am ET
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement
INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision's proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.
Nov 10, 2020 07:00 am ET
Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced financial results for the third quarter ended September 30,...
Nov 03, 2020 07:00 am ET
Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that it will publish financial results for the third...
Oct 15, 2020 07:00 am ET
Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that the U.S. Patent and Trademark...
Oct 14, 2020 07:00 am ET
Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Alex Kelly has been appointed to the...
Sep 28, 2020 07:00 am ET
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced its participation in the following...
Sep 21, 2020 07:00 am ET
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a...
Sep 17, 2020 07:00 am ET
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, in collaboration with Servier, an independent global...
Sep 09, 2020 07:00 am ET
Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the U.S. Food and Drug Administration (FDA) has granted...
Sep 02, 2020 07:00 am ET
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced its participation in the following upcoming investor...
Aug 19, 2020 07:00 am ET
Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the U.S. Food and Drug Administration (FDA) has granted...
Aug 13, 2020 07:00 am ET
Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced financial results for the second quarter ended June 30,...
Aug 04, 2020 07:00 am ET
Elo Life Systems Announces Strategic Partnership with Dole Food Company with the Goal of Saving the Cavendish Banana
Elo Life Systems, a food and agriculture company with a mission to improve human health and wellness, today announced a strategic partnership with the Dole Food Company, one of the world’s largest producers of high-quality fresh fruit and...
Aug 03, 2020 07:00 am ET
Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform today announced it will report financial results for the second quarter of...
Jul 06, 2020 07:00 am ET
Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that the Company will regain full rights and all data it...
Jun 08, 2020 07:00 am ET
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that the first patient has been dosed in a Phase 1/2a...
May 26, 2020 04:01 pm ET
Precision BioSciences to Present at Upcoming Investor Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform today announced its participation in the following upcoming investor...
May 15, 2020 07:00 am ET
Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, today announced financial results for the first quarter ended...
May 07, 2020 07:00 am ET
Precision BioSciences to Report First Quarter 2020 Financial Results and Present at Bank of America Securities Health Care Conference 2020
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that it will report financial results for the...
Apr 28, 2020 04:45 pm ET
Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® gene editing platform, today announced that the Company and its collaborators will present...
Apr 15, 2020 07:00 am ET
Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, today announced that Dora Alvarado has joined the leadership team...
Apr 07, 2020 07:00 am ET
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, today announced the initiation of patient dosing in a Phase 1/2a...
Mar 11, 2020 07:00 am ET
Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, announced today that Geno Germano, President and CEO of Elucida...
Mar 10, 2020 07:05 am ET
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® genome editing platform, today announced financial results for the fourth...
Feb 21, 2020 07:00 am ET
Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that it will publish financial results for the fiscal year and...
Jan 13, 2020 07:00 am ET
Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted...
Jan 06, 2020 07:00 am ET
Precision BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that Matt Kane, co-founder and CEO, will present at the 38th...
Dec 09, 2019 07:00 am ET
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced updated interim clinical data from the ongoing Phase 1 trial of...
Nov 13, 2019 07:00 am ET
Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that Kevin J. Buehler, former CEO of Alcon Laboratories, has...
Nov 12, 2019 07:15 am ET
Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced financial results for the third quarter ended...
Nov 06, 2019 09:01 am ET
Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the Ame
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that initial results from the ongoing Phase 1/2a trial of its...
Oct 30, 2019 06:30 am ET
Precision BioSciences to Report Third Quarter 2019 Financial Results and Present at Upcoming Investor Conferences in November
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that it will publish financial results for the third quarter of...
Sep 30, 2019 06:30 am ET
Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today the appointment of Nicholas Riddle, MB, BChir...
Sep 26, 2019 06:30 am ET
Precision BioSciences to Present at Upcoming Industry and Investor Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that members of its senior leadership team will participate in...
Sep 23, 2019 06:30 am ET
Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that David Thomson, PhD, has been appointed to the position of...
Sep 16, 2019 06:30 am ET
Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced the U.S. Food and Drug Administration (FDA) has accepted its...
Sep 04, 2019 06:30 am ET
Precision BioSciences to Present at Upcoming Scientific Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, is participating in several upcoming presentations on chimeric...
Aug 28, 2019 06:30 am ET
Precision BioSciences to Present at Upcoming Investor Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced that members of its senior management team will...
Aug 14, 2019 04:30 pm ET
Precision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress
Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced financial results for the second quarter ended...
Jul 18, 2019 06:30 am ET
Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS® genome editing platform, announced today the opening of its Manufacturing Center for Advanced...
Jul 10, 2019 03:00 pm ET
Elo Life Systems’ Mario G. Pennisi Awarded BIO Leadership and Legacy Award in Industrial Biotechnology and Agriculture at BIO World Congress
Elo Life Systems Inc. (“Elo”), a wholly owned subsidiary of Precision BioSciences, Inc. (Nasdaq: DTIL) announced today that Mario G. Pennisi, Resident Director of Elo’s Australian subsidiary located in Brisbane, Australia, received the BIO...
Jun 12, 2019 06:30 am ET
Precision BioSciences Appoints Dario Scimeca as General Counsel
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS® genome editing platform, announced today that Dario Scimeca has joined Precision BioSciences as...
May 29, 2019 06:30 am ET
Precision BioSciences to Present at Upcoming Investor Conferences
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS® genome editing platform, today announced that members of its management team will participate in...
May 14, 2019 06:30 am ET
Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer
Precision BioSciences (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its proprietary ARCUS® genome editing platform, announced today that Christopher R. Heery, M.D. has joined Precision BioSciences...
May 09, 2019 06:30 am ET
Precision BioSciences Announces Presentations at the 14th Annual Terrapinn World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome editing platform, announced today that its Chief Scientific Officer, Derek Jantz, Ph.D., and...
Apr 29, 2019 04:15 pm ET
Precision BioSciences Reports First Quarter 2019 Financial Results
Precision BioSciences, a genome editing company dedicated to improving life (Nasdaq: DTIL) (“Precision”) through the application of its proprietary ARCUS genome editing platform, announced today financial and corporate results for the first quarter...
Apr 24, 2019 06:30 am ET
Precision BioSciences Announces Presentations at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy
Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome editing platform, announced today its participation in several preclinical presentations and a...
Apr 17, 2019 05:30 am ET
Precision BioSciences Announces Dosing of First Patient in Off-The-Shelf CAR T Cell Therapy Phase 1/2a Clinical Trial
Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome editing platform, announced today it has dosed the first patient in the Phase 1/2a clinical trial...
Apr 01, 2019 04:05 pm ET
Precision BioSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced the closing of its initial public offering of 9,085,000 shares of...
Mar 27, 2019 05:50 pm ET
Precision BioSciences Announces Pricing of Initial Public Offering
Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced the pricing of its initial public offering of 7,900,000 shares of...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.